Impact of red blood cells count and high density lipoproteins with the prevalence and extent of coronary artery disease

Journal of Thrombosis and Thrombolysis

Volumn 40, Issue 1, 2015, Pages 61-68

  Schaffer, Alon ^a   Verdoia, Monica ^a   Cassetti, Ettore ^a   Barbieri, Lucia ^a   Perrone Filardi, Pasquale ^b   Marino, Paolo ^a   De Luca, Giuseppe ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Coronary angiography; Coronary artery disease; High density lipoprotein; Red blood cells

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; TROPONIN I; HIGH DENSITY LIPOPROTEIN;

AGE DISTRIBUTION; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ERYTHROCYTE COUNT; FEMALE; HUMAN; HYPERTENSION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POPULATION DISTRIBUTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING HABIT; BLOOD; ERYTHROCYTE; METABOLISM; MIDDLE AGED; RISK FACTOR; TRENDS;

AGED; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; ERYTHROCYTE COUNT; ERYTHROCYTES; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 84958110766     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1174-x     Document Type: Article

References (40)

1. Karalis DG (2009) Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. Mayo Clin Proc 84:345–352
2. Libby P (2005) The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 46:1225–1228
3. Miller GJ, Miller NE (1975) Plasma-highdensity- lipoprotein concentration and development of ischaemic heart-disease. Lancet 1:16–19
4. Castelli WP, Garrison RJ, Wilson PW (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256:2835–2838
5. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949–3003
6. Glomset JA (1968) The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 9:155–167
7. Hill SA, McQueen MJ (1997) Reverse cholesterol transport–a review of the process and its clinical implications. Clin Biochem 30:517–525
8. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135
9. Tziakas DN, Kaski JC, Chalikias GK, Romero C, Fredericks S, Tentes IK, Kortsaris AX, Hatseras DI, Holt DW (2007) Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J Am Coll Cardiol 49:2081–2089
10. De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi E, Coppo L, Iorio S, Venegoni L, Rondano E, Dell’Era G, Rizzo C, Pergolini P, Monaco F, Bellomo G, Marino P (2009) Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis 206:292–297
11. De Luca G, Secco GG, Santagostino M, Venegoni L, Iorio S, Cassetti E, Verdoia M, Coppo L, Di Mario C, Bellomo G, Marino P, Novara Atherosclerosis Study Group (NAS) (2012) Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 22:426–433
12. De Luca G, van ‘t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H (2005) Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty Eur Heart J 26:662–666
13. De Luca G, Verdoia M, Suryapranata H (2012) Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis 222:426–433
14. De Luca G, Dirksen M, Spaulding C (2012) Drug-eluting versus bare metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 172:611–621
15. De Luca G, Ernst N, van’t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H (2006) Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J 151:1256–1259
16. De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van’t Hof AW (2009) Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 207:181–185
17. De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, Marino P, Novara Atherosclerosis Study Group (NAS) (2011) High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 31:458–463
18. De Luca G, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdoia M, Schaffer A, Coppo L, Bellomo G, Marino P, Novara Atherosclerosis Study Group (2010) Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets 21:508–514
19. De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Coppo L, Schaffer A, Fundaliotis A, Iorio S, Venegoni L, Bellomo G, Marino P (2010) Platelet-large cell ratio and the extent of coronary artery disease: results from a large prospective study. J Thromb Thrombolysis 30:426–433
20. Gordon DJ, Rifkind BM (1989) High-density lipoproteindthe clinical implications of recent studies. N Engl J Med 321:1311–1316
21. Assman G, Cullen P, Schulte H (1998) The Münster Heart Study (PROCAM), results of follow-up at 8 years. Eur Heart J 19:A2–A11
22. Cziraky MJ, Watson KE, Talbert RL (2008) Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 14:S3–28
23. High patient compliance with nicacin/laropiprant in large clinical trial interim safety and tolerability results from HPS-2 THRIVE study released at 2012 ESC congress: drug trends in cardiology. (2012) Cardiovasc J Afr 23: 471
24. Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP, Kostuk W, Spertus JA, Dada M, Chaitman BR, Mancini GB, Weintraub WS (2013) Low levels of high density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post hoc analysis from the COURAGE Trial. J Am Coll Cardiol 62:1826–1833
25. Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116:3090–3100
26. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr (1982) Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 2:16–26
27. Buchwald H, O’Dea TJ, Menchaca HJ, Michalek VN, Rohde TD (2000) Effect of plasma cholesterol on red blood cell oxygen transport. Clin Exp Pharmacol Physiol 27:951–955
28. Nara M, Sumino H, Nara M, Machida T, Amagai H, Nakajima K, Murakami M (2009) Impaired blood rheology and elevated remnant-like lipoprotein particle cholesterol in hypercholesterolaemic subjects. J Int Med Res 37:308–317
29. Schaffer A, Verdoia M, Barbieri L, Aprami TM, Suryapranata H, Marino P, De Luca G; on behalf of the Novara Atherosclerosis Study Group (NAS) (2013) High-density lipoproteins and coronary artery disease: a Single-Center Cohort Study. Angiology 18. [Epub ahead of print]
30. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R (2003) Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349:2316–2325
31. Asterkamp G, Virmani R (2002) The erythrocyte: a new player in atheromatous core formation. Heart 88:115–116
32. Steinvil A, Rogowski O, Banai S, Leshem-Rubinow E, Halkin A, Keren G, Finkelstein A, Mashav N, Zuzut M, Berliner S, Arbel Y (2015) Anemia and inflammation have an additive value in risk stratification of patients undergoing coronary interventions. J Cardiovasc Med (Hagerstown) 16:106–111
33. Kitai Y, Ozasa N, Morimoto T, Bao B, Furukawa Y, Nakagawa Y, Kadota K, Yanagita M, Shizuta S, Kimura T; CREDO-Kyoto registry investigators (2013) Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention. Int J Cardiol 168:5221–5228
34. Ganelina IE, Rodionova VI, Katiukhin LN, Tepliakov DV (2011) Data of coronary angiography and rheological properties of erythrocytes in non ST-elevation acute coronary syndrome. Kardiologiia 51:4–9
35. Madjid M, Fatemi O (2013) Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update. Tex Heart Inst J 40:17–29
36. Hung KT, Berisha SZ, Ritchey BM, Santore J, Smith JD (2012) Red blood cells play a role in reverse cholesterol transport. Arterioscler Thromb Vasc Biol 32:1460–1465
37. Nikolić M, Stanić D, Antonijević N, Niketić V (2004) Cholesterol bound to hemoglobinin normal human erythrocytes: a new form of cholesterol in circulation? Clin Biochem 37:22–26
38. Levy Y, Leibowitz R, Aviram M, Brook JG, Cogan U (1992) Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia. Br J Clin Pharmacol 34:427–430
39. Martínez M, Vayá A, Martí R, Gil L, Lluch I, Carmena R, Aznar J (1996) Erythrocyte membrane cholesterol/phospholipid changes and hemorheological modifications in familial hypercholesterolemia treated with lovastatin. Thromb Res 83:375–388
40. Hassani SE, Mintz GS, Fong HS, Kim SW, Xue Z, Pichard AD (2006) Negative remodeling and calcified plaque in octogenarians with acute myocardial infarction: an intravascular ultrasound analysis. J Am Coll Cardiol 47:2413–2419